These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related]
4. Modulators of CFTR. Updates on clinical development and future directions. Bardin E; Pastor A; Semeraro M; Golec A; Hayes K; Chevalier B; Berhal F; Prestat G; Hinzpeter A; Gravier-Pelletier C; Pranke I; Sermet-Gaudelus I Eur J Med Chem; 2021 Mar; 213():113195. PubMed ID: 33524685 [TBL] [Abstract][Full Text] [Related]
5. Cystic fibrosis papers of the year 2017. Doull I Paediatr Respir Rev; 2018 Jun; 27():2-5. PubMed ID: 29627168 [TBL] [Abstract][Full Text] [Related]
6. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel. Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400 [TBL] [Abstract][Full Text] [Related]
7. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation. Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700 [TBL] [Abstract][Full Text] [Related]
8. The use of lumacaftor/ivacaftor to treat acute deterioration in paediatric cystic fibrosis. Hammond JA; Connett GJ Paediatr Respir Rev; 2018 Jun; 27():16-17. PubMed ID: 29914743 [TBL] [Abstract][Full Text] [Related]
9. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation. Bulloch MN; Hanna C; Giovane R Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346 [TBL] [Abstract][Full Text] [Related]
10. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy. Lommatzsch ST; Taylor-Cousar JL Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466 [TBL] [Abstract][Full Text] [Related]
11. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction. Brewington JJ; McPhail GL; Clancy JP Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802 [TBL] [Abstract][Full Text] [Related]
12. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis. Guerra L; Favia M; Di Gioia S; Laselva O; Bisogno A; Casavola V; Colombo C; Conese M Expert Opin Drug Discov; 2020 Aug; 15(8):873-891. PubMed ID: 32290721 [TBL] [Abstract][Full Text] [Related]
13. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor? Schneider EK; Reyes-Ortega F; Li J; Velkov T Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127 [TBL] [Abstract][Full Text] [Related]
14. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review. Yang H; Ma T Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311 [TBL] [Abstract][Full Text] [Related]
15. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy. Connett GJ Drug Des Devel Ther; 2019; 13():2405-2412. PubMed ID: 31409974 [TBL] [Abstract][Full Text] [Related]
16. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Kuk K; Taylor-Cousar JL Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827 [TBL] [Abstract][Full Text] [Related]
17. Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum. Habler K; Kalla AS; Rychlik M; Bruegel M; Teupser D; Nährig S; Vogeser M; Paal M Clin Chem Lab Med; 2022 Jan; 60(1):82-91. PubMed ID: 34668357 [TBL] [Abstract][Full Text] [Related]
18. Metabolomic responses to lumacaftor/ivacaftor in cystic fibrosis. Kopp BT; McCulloch S; Shrestha CL; Zhang S; Sarzynski L; Woodley FW; Hayes D Pediatr Pulmonol; 2018 May; 53(5):583-591. PubMed ID: 29461009 [TBL] [Abstract][Full Text] [Related]
19. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist. Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995 [TBL] [Abstract][Full Text] [Related]
20. Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa. Barnaby R; Koeppen K; Nymon A; Hampton TH; Berwin B; Ashare A; Stanton BA Am J Physiol Lung Cell Mol Physiol; 2018 Mar; 314(3):L432-L438. PubMed ID: 29146575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]